Hagop Kantarjian, MD, on Treating Philadelphia Chromosome–Positive ALL

2014 ASH Annual Meeting

Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 797, “First Results of the Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Patients,” presented by Sabina Chiaretti, MD, PhD, and abstract 798, “Nilotinib and Chemotherapy for First-Line Treatment in Elderly Patients with De Novo Philadelphia Chromosome/BCR-ABL1–Positive Acute Lymphoblastic Leukemia (ALL): A Trial of the European Working Group for Adult ALL (EWALL-PH-02),” presented by Oliver G. Ottman, MD.

Matthew Lunning, DO, on Ublituximab Plus TGR-1202 in Lymphoma

Matthew Lunning, DO, of the University of Nebraska Medical Center, on abstract 801, “Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with TGR-1202, a Next-Generation Once Daily PI3kδ Inhibitor, Demonstrates Activity in Heavily Pretreated and High-Risk Chronic Lymphocytic Leukemia and B-Cell Lymphoma.”

Hematologic Malignancies

Keith McCrae, MD

Keith McCrae, MD, on Splenectomy in Immune Thrombocytopenia

Keith McCrae, MD, of the Cleveland Clinic, offers his thoughts on abstract 232, “Long-Term Complications After Splenectomy in Adult Chronic Immune Thrombocytopenia With a Minimum Follow-up of 10 Years: First Results From a Single-Center Case-Control Study in 140 Patients With Primary ITP,” presented by Lan-huong Thai.

Leukemia

Hagop Kantarjian, MD

Hagop Kantarjian, MD, on Inotuzumab Ozogamicin Plus Low-Intensity Chemotherapy in ALL

Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 794, “Inotuzumab Ozogamicin in Combination With Low-Intensity Chemotherapy (Mini-Hyper-CVD) as Front-Line Therapy for Older Patients (≥ 60 years) With Acute Lymphoblastic Leukemia,” presented by Elias Jabbour, MD.

Lymphoma

James O. Armitage, MD, FACP, FRCP, and Bertrand Coiffier, MD, PhD

James O. Armitage, MD, FACP, FRCP, and Bertrand Coiffier, MD, PhD, on Managing Lymphoma: The French Perspective

James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Bertrand Coiffier, MD, PhD, of the Centre Hospitalier Lyon-Sud discuss three French studies on rituximab maintenance vs wait and watch after R-DHAP in mantle cell lymphoma; R-CHOP with or without radiotherapy in diffuse large B-cell lymphoma; and romidepsin and CHOP in peripheral T-cell lymphoma.

Leukemia

Myelodysplastic Syndromes

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Clinical Trial Results for AML, MDS, and CMML Treatment

James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Richard M. Stone, MD of the Dana-Farber Cancer Institute, discuss three clinical trials: different doses of daunorubicin for AML; comparing azacitidine plus lenolidomide to vorinostat vs azacitidine monotherapy in MDS and CMML; and sorafenib vs placebo in addition to standard treatment for AML.

Jan

Today In Oncology

Hagop Kantarjian, MD, on Treating Philadelphia Chromosome–Positive ALL

Related Videos

Matthew Lunning, DO, on Ublituximab Plus TGR-1202 in Lymphoma

Keith McCrae, MD, on Splenectomy in Immune Thrombocytopenia

Hagop Kantarjian, MD, on Inotuzumab Ozogamicin Plus Low-Intensity Chemotherapy in ALL

James O. Armitage, MD, FACP, FRCP, and Bertrand Coiffier, MD, PhD, on Managing Lymphoma: The French Perspective

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Clinical Trial Results for AML, MDS, and CMML Treatment

Tislelizumab Plus Chemotherapy Improves Progression-Free Survival in Nasopharyngeal Cancer

Treatment De-escalation in HPV-Associated Oropharyngeal Cancer Using Primary Radiotherapy vs Transoral Surgery

Gabapentin May Be an Effective Alternative to Opioids for Patients With Head and Neck Cancer Receiving Radiation

Role of Combined Positive Score With Treatment Outcomes in Recurrent or Metastatic Head and Neck Cancer

Study Finds Black and Hispanic Men With Throat Cancer Are Experiencing Higher Mortality White Men Are Increasingly Being Diagnosed at a Late Stage